Current Diabetes Reports

, 14:486

FTO and Obesity: Mechanisms of Association

  • Xu Zhao
  • Ying Yang
  • Bao-Fa Sun
  • Yong-Liang Zhao
  • Yun-Gui Yang
Obesity (J McCaffery, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Obesity

Abstract

The Fat mass and obesity associated (FTO) gene is a newly identified genetic factor for obesity. However, the exact molecular mechanisms responsible for the effect of FTO on obesity remain largely unknown. Recent studies from genome-wide associated studies reveal that genetic variants in the FTO gene are associated not only with human adiposity and metabolic disorders, but also with cancer, a highly obesity-associated disease as well. Data from animal and cellular models further demonstrate that the perturbation of FTO enzymatic activity dysregulates genes related to energy metabolism, causing the malfunction of energy and adipose tissue homeostasis in mice. The most significant advance about FTO research is the recent discovery of FTO as the first N6-methyl-adenosine (m6A) RNA demethylase that catalyzes the m6A demethylation in α-ketoglutarate - and Fe2+-dependent manners. This finding provides the strong evidence that the dynamic and reversible chemical m6A modification on RNA may act as a novel epitranscriptomic marker. Furthermore, the FTO protein was observed to be partially localized onto nuclear speckles enriching mRNA processing factors, implying a potential role of FTO in regulating RNA processing. This review summarizes the recent progress about biological functions of FTO through disease-association studies as well as the data from in vitro and in vivo models, and highlights the biochemical features of FTO that might be linked to obesity.

Keywords

FTO Obesity N6-methyl-adenosine (m6A) RNA methylation Epitranscriptome 

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Morabia A, Abel T. The WHO report “Preventing chronic diseases: a vital investment” and us. Soz Praventivmed. 2006;51:74.PubMedCrossRefGoogle Scholar
  2. 2.
    Herrera BM, Keildson S, Lindgren CM. Genetics and epigenetics of obesity. Maturitas. 2011;69:41–9.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.•
    Dai HJ, Wu JC, Tsai RT, et al. T-HOD: a literature-based candidate gene database for hypertension, obesity and diabetes. Database. 2013;2013:bas061. The authors established the T-HOD database providing the most detailed summary of obesity associated gene loci and polymorphisms uncovered to date. Google Scholar
  4. 4.
    Rankinen T, Zuberi A, Chagnon YC, et al. The human obesity gene map: the 2005 update. Obesity. 2006;14:529–644.PubMedCrossRefGoogle Scholar
  5. 5.
    Loos RJ, Bouchard C. FTO: the first gene contributing to common forms of human obesity. Obes Rev. 2008;9:246–50.PubMedCrossRefGoogle Scholar
  6. 6.
    Scuteri A, Sanna S, Chen WM, et al. Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-related traits. PLoS Genet. 2007;3:e115.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Hinney A, Nguyen TT, Scherag A, et al. Genome wide association (GWA) study for early onset extreme obesity supports the role of fat mass and obesity associated gene (FTO) variants. PLoS One. 2007;2:e1361.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Frayling TM, Timpson NJ, Weedon MN, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science. 2007;316:889–94.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Dina C, Meyre D, Gallina S, et al. Variation in FTO contributes to childhood obesity and severe adult obesity. Nat Genet. 2007;39:724–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Yang J, Loos RJ, Powell JE, et al. FTO genotype is associated with phenotypic variability of body mass index. Nature. 2012;490:267–72.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Wojciechowski P, Lipowska A, Rys P, et al. Impact of FTO genotypes on BMI and weight in polycystic ovary syndrome: a systematic review and meta-analysis. Diabetologia. 2012;55:2636–45.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Speakman JR, Rance KA, Johnstone AM. Polymorphisms of the FTO gene are associated with variation in energy intake, but not energy expenditure. Obesity. 2008;16:1961–5.PubMedCrossRefGoogle Scholar
  13. 13.
    Speakman JR. FTO effect on energy demand vs food intake. Nature. 2010;464:E1; discussion E2.Google Scholar
  14. 14.
    Wardle J, Llewellyn C, Sanderson S, et al. The FTO gene and measured food intake in children. Int J Obes. 2009;33:42–5.CrossRefGoogle Scholar
  15. 15.
    Cecil JE, Tavendale R, Watt P, et al. An obesity-associated FTO gene variant and increased energy intake in children. N Engl J Med. 2008;359:2558–66.PubMedCrossRefGoogle Scholar
  16. 16.
    de Luis DA, Aller R, Conde R, et al. The rs9939609 gene variant in FTO modified the metabolic response of weight loss after a 3-month intervention with a hypocaloric diet. J Investig Med. 2013;61:22–6.PubMedGoogle Scholar
  17. 17.
    Haupt A, Thamer C, Staiger H, et al. Variation in the FTO gene influences food intake but not energy expenditure. Exp Clin Endocrinol Diabetes. 2009;117:194–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Li H, Wu Y, Loos RJ, et al. Variants in the fat mass- and obesity-associated (FTO) gene are not associated with obesity in a Chinese Han population. Diabetes. 2008;57:264–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Chang YC, Liu PH, Lee WJ, et al. Common variation in the fat mass and obesity-associated (FTO) gene confers risk of obesity and modulates BMI in the Chinese population. Diabetes. 2008;57:2245–52.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Cheung CY, Tso AW, Cheung BM, et al. Obesity susceptibility genetic variants identified from recent genome-wide association studies: implications in a Chinese population. J Clin Endocrinol Metab. 2010;95:1395–403.PubMedCrossRefGoogle Scholar
  21. 21.
    Tews D, Fischer-Posovszky P, Wabitsch M. Regulation of FTO and FTM expression during human pre-adipocyte differentiation. Horm Metab Res. 2011;43:17–21.PubMedCrossRefGoogle Scholar
  22. 22.
    Wahlen K, Sjolin E, Hoffstedt J. The common rs9939609 gene variant of the fat mass- and obesity-associated gene FTO is related to fat cell lipolysis. J Lipid Res. 2008;49:607–11.PubMedCrossRefGoogle Scholar
  23. 23.
    Lappalainen T, Kolehmainen M, Schwab U, et al. Gene expression of FTO in human subcutaneous adipose tissue, peripheral blood mononuclear cells and adipocyte cell line. J Nutrigenet Nutrigenomics. 2010;3:37–45.PubMedCrossRefGoogle Scholar
  24. 24.
    Grunnet LG, Nilsson E, Ling C, et al. Regulation and function of FTO mRNA expression in human skeletal muscle and subcutaneous adipose tissue. Diabetes. 2009;58:2402–8.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Kloting N, Schleinitz D, Ruschke K, et al. Inverse relationship between obesity and FTO gene expression in visceral adipose tissue in humans. Diabetologia. 2008;51:641–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Labayen I, Ruiz JR, Ortega FB, et al. Association between the FTO rs9939609 polymorphism and leptin in European adolescents: a possible link with energy balance control. The HELENA study. Int J Obes. 2011;35:66–71.CrossRefGoogle Scholar
  27. 27.
    Timpson NJ, Emmett PM, Frayling TM, et al. The fat mass- and obesity-associated locus and dietary intake in children. Am J Clin Nutr. 2008;88:971–8.PubMedGoogle Scholar
  28. 28.
    Zeggini E, Weedon MN, Lindgren CM, et al. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science. 2007;316:1336–41.PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Scott LJ, Mohlke KL, Bonnycastle LL, et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science. 2007;316:1341–5.PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Samaras K, Botelho NK, Chisholm DJ, et al. Subcutaneous and visceral adipose tissue FTO gene expression and adiposity, insulin action, glucose metabolism, and inflammatory adipokines in type 2 diabetes mellitus and in health. Obes Surg. 2010;20:108–13.PubMedCrossRefGoogle Scholar
  31. 31.
    Li T, Wu K, You L, et al. Common variant rs9939609 in gene FTO confers risk to polycystic ovary syndrome. PLoS One. 2013;8:e66250.PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Li X, Liang L, Zhang M, et al. Obesity-related genetic variants, human pigmentation, and risk of melanoma. Hum Genet. 2013.Google Scholar
  33. 33.
    Iles MM, Law MH, Stacey SN, et al. A variant in FTO shows association with melanoma risk not due to BMI. Nat Genet. 2013;45:428–32, 432e1.Google Scholar
  34. 34.
    Kaklamani V, Yi N, Sadim M, et al. The role of the fat mass and obesity associated gene (FTO) in breast cancer risk. BMC Med Genet. 2011;12:52.PubMedCentralPubMedCrossRefGoogle Scholar
  35. 35.
    Lurie G, Gaudet MM, Spurdle AB, et al. The obesity-associated polymorphisms FTO rs9939609 and MC4R rs17782313 and endometrial cancer risk in non-Hispanic white women. PLoS One. 2011;6:e16756.PubMedCentralPubMedCrossRefGoogle Scholar
  36. 36.
    Delahanty RJ, Beeghly-Fadiel A, Xiang YB, et al. Association of obesity-related genetic variants with endometrial cancer risk: a report from the Shanghai Endometrial Cancer Genetics Study. Am J Epidemiol. 2011;174:1115–26.PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Tang H, Dong X, Hassan M, et al. Body mass index and obesity- and diabetes-associated genotypes and risk for pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2011;20:779–92.PubMedCentralPubMedCrossRefGoogle Scholar
  38. 38.
    Pierce BL, Austin MA, Ahsan H. Association study of type 2 diabetes genetic susceptibility variants and risk of pancreatic cancer: an analysis of PanScan-I data. Cancer Causes Control. 2011;22:877–83.PubMedCrossRefGoogle Scholar
  39. 39.
    Meyer TE, Boerwinkle E, Morrison AC, et al. Diabetes genes and prostate cancer in the Atherosclerosis Risk in Communities study. Cancer Epidemiol Biomarkers Prev. 2010;19:558–65.PubMedCentralPubMedCrossRefGoogle Scholar
  40. 40.
    Lewis SJ, Murad A, Chen L, et al. Associations between an obesity related genetic variant (FTO rs9939609) and prostate cancer risk. PLoS One. 2010;5:e13485.PubMedCentralPubMedCrossRefGoogle Scholar
  41. 41.
    Tarabra E, Actis GC, Fadda M, et al. The obesity gene and colorectal cancer risk: a population study in Northern Italy. Eur J Intern Med. 2012;23:65–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Nock NL, Plummer SJ, Thompson CL, et al. FTO polymorphisms are associated with adult body mass index (BMI) and colorectal adenomas in African-Americans. Carcinogenesis. 2011;32:748–56.PubMedCentralPubMedCrossRefGoogle Scholar
  43. 43.
    Brennan P, McKay J, Moore L, et al. Obesity and cancer: Mendelian randomization approach utilizing the FTO genotype. Int J Epidemiol. 2009;38:971–5.PubMedCentralPubMedCrossRefGoogle Scholar
  44. 44.
    Li GQ, Chen QW, Wang L, et al. Association between FTO gene polymorphism and cancer risk: evidence from 16,277 cases and 31,153 controls. Tumor Biol. 2012;33:1237–43.CrossRefGoogle Scholar
  45. 45.
    Ho AJ, Stein JL, Hua X, et al. A commonly carried allele of the obesity-related FTO gene is associated with reduced brain volume in the healthy elderly. Proc Natl Acad Sci U S A. 2010;107:8404–9.PubMedCentralPubMedCrossRefGoogle Scholar
  46. 46.
    Keller L, Xu W, Wang HX, et al. The obesity related gene, FTO, interacts with APOE, and is associated with Alzheimer’s disease risk: a prospective cohort study. J Alzheimers Dis. 2011;23:461–9.PubMedGoogle Scholar
  47. 47.
    Fischer J, Koch L, Emmerling C, et al. Inactivation of the FTO gene protects from obesity. Nature. 2009;458:894–8.PubMedCrossRefGoogle Scholar
  48. 48.
    Tews D, Fischer-Posovszky P, Fromme T, et al. FTO deficiency induces UCP-1 expression and mitochondrial uncoupling in adipocytes. Endocrinology. 2013.Google Scholar
  49. 49.
    Gao X, Shin YH, Li M, et al. The fat mass and obesity associated gene FTO functions in the brain to regulate postnatal growth in mice. PLoS One. 2010;5:e14005.PubMedCentralPubMedCrossRefGoogle Scholar
  50. 50.
    Church C, Lee S, Bagg EA, et al. A mouse model for the metabolic effects of the human fat mass and obesity associated FTO gene. PLoS Genet. 2009;5:e1000599.PubMedCentralPubMedCrossRefGoogle Scholar
  51. 51.
    Church C, Moir L, McMurray F, et al. Overexpression of FTO leads to increased food intake and results in obesity. Nat Genet. 2010;42:1086–92.PubMedCentralPubMedCrossRefGoogle Scholar
  52. 52.
    McMurray F, Church CD, Larder R, et al. Adult onset global loss of the FTO gene alters body composition and metabolism in the mouse. PLoS Genet. 2013;9:e1003166.PubMedCentralPubMedCrossRefGoogle Scholar
  53. 53.••
    Hess ME, Hess S, Meyer KD, et al. The fat mass and obesity associated gene (FTO) regulates activity of the dopaminergic midbrain circuitry. Nat Neurosci. 2013;16:1042–8. These authors reported, for the first time, that FTO regulates the demethylation of specific mRNAs in vivo and dopaminergic transmission activity. PubMedCrossRefGoogle Scholar
  54. 54.
    Johnson PM, Kenny PJ. Dopamine D2 receptors in addiction-like reward dysfunction and compulsive eating in obese rats. Nat Neurosci. 2010;13:635–41.PubMedCentralPubMedCrossRefGoogle Scholar
  55. 55.
    Wang GJ, Volkow ND, Logan J, et al. Brain dopamine and obesity. Lancet. 2001;357:354–7.Google Scholar
  56. 56.
    Wu Q, Saunders RA, Szkudlarek-Mikho M, et al. The obesity-associated FTO gene is a transcriptional co-activator. Biochem Biophys Res Commun. 2010;401:390–5.PubMedCentralPubMedCrossRefGoogle Scholar
  57. 57.
    Kirkpatrick CL, Marchetti P, Purrello F, et al. Type 2 diabetes susceptibility gene expression in normal or diabetic sorted human alpha and beta cells: correlations with age or BMI of islet donors. PLoS One. 2010;5:e11053.PubMedCentralPubMedCrossRefGoogle Scholar
  58. 58.
    Poritsanos NJ, Lew PS, Mizuno TM. Relationship between blood glucose levels and hepatic FTO mRNA expression in mice. Biochem Biophys Res Commun. 2010;400:713–7.PubMedCrossRefGoogle Scholar
  59. 59.
    Berulava T, Ziehe M, Klein-Hitpass L, et al. FTO levels affect RNA modification and the transcriptome. Eur J Hum Genet. 2012;21:317–23.PubMedCentralPubMedCrossRefGoogle Scholar
  60. 60.
    Tung YC, Ayuso E, Shan X, et al. Hypothalamic-specific manipulation of FTO, the ortholog of the human obesity gene FTO, affects food intake in rats. PLoS One. 2010;5:e8771.PubMedCentralPubMedCrossRefGoogle Scholar
  61. 61.
    McTaggart JS, Lee S, Iberl M, et al. FTO is expressed in neurons throughout the brain and its expression is unaltered by fasting. PLoS One. 2011;6:e27968.PubMedCentralPubMedCrossRefGoogle Scholar
  62. 62.
    Cheung MK, Gulati P, O’Rahilly S, et al. FTO expression is regulated by availability of essential amino acids. Int J Obes. 2013;37:744–7.CrossRefGoogle Scholar
  63. 63.
    Gulati P, Cheung MK, Antrobus R, et al. Role for the obesity-related FTO gene in the cellular sensing of amino acids. Proc Natl Acad Sci U S A. 2013;110:2557–62.PubMedCentralPubMedCrossRefGoogle Scholar
  64. 64.
    Wang P, Yang FJ, Du H, et al. Involvement of leptin receptor long isoform (LepRb)-STAT3 signaling pathway in brain fat mass- and obesity-associated (FTO) downregulation during energy restriction. Mol Med. 2011;17:523–32.PubMedCentralPubMedGoogle Scholar
  65. 65.
    Rask-Andersen M, Almen MS, Olausen HR, et al. Functional coupling analysis suggests link between the obesity gene FTO and the BDNF-NTRK2 signaling pathway. BMC Neurosci. 2011;12:117.PubMedCentralPubMedCrossRefGoogle Scholar
  66. 66.
    Vujovic P, Stamenkovic S, Jasnic N, et al. Fasting induced cytoplasmic FTO expression in some neurons of rat hypothalamus. PLoS One. 2013;8:e63694.PubMedCentralPubMedCrossRefGoogle Scholar
  67. 67.••
    Jia GF, Fu Y, Zhao X, et al. N6-Methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nature Chem Biol. 2011;7:885–7. This finding unveiled the physiological RNA modification substrate, m6A, of FTO in vivo and in vitro for the first time. CrossRefGoogle Scholar
  68. 68.
    Gerken T, Girard CA, Tung YC, et al. The obesity-associated FTO gene encodes a 2-oxoglutarate-dependent nucleic acid demethylase. Science. 2007;318:1469–72.PubMedCentralPubMedCrossRefGoogle Scholar
  69. 69.
    Jia G, Yang CG, Yang S, et al. Oxidative demethylation of 3-methylthymine and 3-methyluracil in single-stranded DNA and RNA by mouse and human FTO. FEBS Lett. 2008;582:3313–9.PubMedCentralPubMedCrossRefGoogle Scholar
  70. 70.
    Han Z, Niu T, Chang J, et al. Crystal structure of the FTO protein reveals basis for its substrate specificity. Nature. 2010;464:1205–9.PubMedCrossRefGoogle Scholar
  71. 71.••
    Meyer KD, Saletore Y, Zumbo P, et al. Comprehensive analysis of mRNA methylation reveals enrichment in 3’ UTRs and near stop codons. Cell. 2012;149:1635–46. It is one of the 2 papers describing the genome-wide distribution of m6A sites in mRNAs. It further shows that m6A sites are enriched near stop codons and in 3’ UTRs. PubMedCentralPubMedCrossRefGoogle Scholar
  72. 72.
    Saletore Y, Meyer K, Korlach J, et al. The birth of the Epitranscriptome: deciphering the function of RNA modifications. Genome Biol. 2012;13:175.PubMedCentralPubMedCrossRefGoogle Scholar
  73. 73.
    Zheng G, Dahl JA, Niu Y, et al. Sprouts of RNA epigenetics: the discovery of mammalian RNA demethylases. RNA Biol. 2013;10.Google Scholar
  74. 74.
    Pan T. N6-methyl-adenosine modification in messenger and long non-coding RNA. Trends Biochem Sci. 2013;38:204–9.PubMedCentralPubMedCrossRefGoogle Scholar
  75. 75.
    Niu Y, Zhao X, Wu YS, et al. N6-methyl-adenosine (m6A) in RNA: an old modification with a novel epigenetic function. Genomics Proteomics Bioinformatics. 2013;11:8–17.PubMedCrossRefGoogle Scholar
  76. 76.
    Jia G, Fu Y, He C. Reversible RNA adenosine methylation in biological regulation. Trends Genet. 2013;29:108–15.PubMedCentralPubMedCrossRefGoogle Scholar
  77. 77.
    Fu Y, He C. Nucleic acid modifications with epigenetic significance. Curr Opin Chem Biol. 2012;16:516–24.PubMedCentralPubMedCrossRefGoogle Scholar
  78. 78.••
    Fu Y, Jia GF, Pang XQ, et al. FTO-mediated formation of N6-hydroxymethyladenosine and N6-formyladenosine in mammalian RNA. Nat Commun. 2013;4:1798. The authors uncovered new intermediate modifications in the demethylation process from m6A to A by FTO. PubMedCentralPubMedCrossRefGoogle Scholar
  79. 79.
    Wei CM, Gershowitz A, Moss B. Methylated nucleotides block 5′ terminus of HeLa cell messenger RNA. Cell. 1975;4:379–86.PubMedCrossRefGoogle Scholar
  80. 80.
    Perry RP, Kelley DE, Friderici K, et al. The methylated constituents of L cell messenger RNA: evidence for an unusual cluster at the 5′ terminus. Cell. 1975;4:387–94.PubMedCrossRefGoogle Scholar
  81. 81.
    Desrosiers RC, Friderici KH, Rottman FM. Characterization of Novikoff hepatoma mRNA methylation and heterogeneity in the methylated 5′ terminus. Biochemistry. 1975;14:4367–74.PubMedCrossRefGoogle Scholar
  82. 82.••
    Dominissini D, Moshitch-Moshkovitz S, Schwartz S, et al. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature. 2012;485:201–6. This is the first report on the landscape of m6A in mRNAs through an antibody-based genome-wide sequencing method. PubMedCrossRefGoogle Scholar
  83. 83.
    Gulati P, Yeo GS. The biology of FTO: from nucleic acid demethylase to amino acid sensor. Diabetologia. 2013.Google Scholar
  84. 84.
    Bokar JA, Shambaugh ME, Polayes D, et al. Purification and cDNA cloning of the AdoMet-binding subunit of the human mRNA (N6-adenosine)-methyltransferase. RNA. 1997;3:1233–47.PubMedCentralPubMedGoogle Scholar
  85. 85.
    Zheng G, Dahl JA, Niu Y, et al. ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. Mol Cell. 2013;49:18–29.PubMedCentralPubMedGoogle Scholar
  86. 86.
    Liu J, Yue Y, Han D, et al. A METTL3-METTL14 complex mediates mammalian nuclear RNA N-adenosine methylation. Nat Chem Biol. 2013;10:93–5.Google Scholar
  87. 87.
    Ping XL, Sun BF, Wang L, et al. Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase. Cell Res. 2014;24:177–89.Google Scholar
  88. 88.
    Egger G, Liang G, Aparicio A, et al. Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004;429:457–63.PubMedCrossRefGoogle Scholar
  89. 89.
    Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol. 2010;28:1057–68.PubMedCrossRefGoogle Scholar
  90. 90.
    Baltz AG, Munschauer M, Schwanhausser B, et al. The mRNA-bound proteome and its global occupancy profile on protein-coding transcripts. Mol Cell. 2012;46:674–90.PubMedCrossRefGoogle Scholar
  91. 91.
    Vilfan ID, Tsai YC, Clark TA, et al. Analysis of RNA base modification and structural rearrangement by single-molecule real-time detection of reverse transcription. J Nanobiotechnology. 2013;11:8.PubMedCentralPubMedCrossRefGoogle Scholar
  92. 92.
    Clark TA, Lu X, Luong K, et al. Enhanced 5-methylcytosine detection in single-molecule, real-time sequencing via Tet1 oxidation. BMC Biol. 2013;11:4.PubMedCentralPubMedCrossRefGoogle Scholar
  93. 93.
    Song CX, Clark TA, Lu XY, et al. Sensitive and specific single-molecule sequencing of 5-hydroxymethylcytosine. Nat Methods. 2012;9:75–7.CrossRefGoogle Scholar
  94. 94.
    Chen B, Ye F, Yu L, et al. Development of cell-active N6-methyladenosine RNA demethylase FTO inhibitor. J Am Chem Soc. 2012;134:17963–71.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Xu Zhao
    • 1
    • 2
  • Ying Yang
    • 1
    • 2
  • Bao-Fa Sun
    • 1
  • Yong-Liang Zhao
    • 1
  • Yun-Gui Yang
    • 1
    • 2
  1. 1.Laboratory of Genome Variations and Precision BiomedicineBeijing Institute of Genomics, Chinese Academy of SciencesBeijingChina
  2. 2.University of Chinese Academy of SciencesBeijingPeople’s Republic of China

Personalised recommendations